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Purpose: Carboplatin-based regimens have proven efficacy in children with cancer.
However, the development of hypersensitivity reactions (HSRs) may have a negative
impact on treatment intensity and patients’ outcome. The aim of this review is to
summarize the incidence and the clinical features of HSRs occurring in children with
cancer treated with carboplatin and their impact on treatment efficacy.
Methods: Data were collected by searching for relevant studies on the incidence,
clinical features and management of possible side effects about the use of carboplatin
in children, published from March 1987 to October 2016 in the PubMed database.
Results: Carboplatin HSRs present with mild/moderate to severe clinical patterns.
The risk of HSR is related to the cumulative number of infusions. Moreover, a greater
risk of developing an HSR has been observed in younger patients than in older age
groups of children; risk is also greater in girls and in patients with a prior history
of allergy to other drugs. Management options include cessation of carboplatin and
switching to another agent, premedication with antihistamines and/or corticosteroids,
and carboplatin desensitization. For sensitized patients who have obtained benefits from
carboplatin, the continuation of the treatment is desirable and desensitization protocols
have showed promising results.
Conclusion: Clinicians must not underestimate the potential risk and occurrence of
carboplatin HSRs in the pediatric population in order to outline adequate management
strategies. Desensitization protocols should be considered for patients sensitive to
carboplatin in order to avoid having to discontinue an effective chemotherapy.
Keywords: hypersensitivity reactions, carboplatin, children, management, desensitization
INTRODUCTION
Carboplatin is a second-generation platinum compound developed to reduce the side effects of
cisplatin, particularly neurotoxicity, nephrotoxicity and emesis, while maintaining comparable
antitumor activity and effectiveness. Carboplatin is widely used to treat solid tumors in adults,
especially for ovarian and lung cancer, and for several types of malignancies in children such as
brain tumor, neuroblastoma, retinoblastoma, germ cell tumors, and hepatoblastoma. Moreover,
the treatment protocol based upon the combination of carboplatin and vincristine reported by
Packer et al. (1997) seems to produce consistent and long-lasting responses in children with low
grade glioma (LGG) (Chiaretti et al., 2004; Trisciuzzi et al., 2004). This is the most widely adopted
chemotherapy for childhood LGG, offering high objective response rates in relapsed and newly
diagnosed patients of 52 and 62%, respectively.
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Carboplatin has been used with increasing frequency for
the management of childhood cancers, and hypersensitivity
reactions (HSRs) have consequently emerged as a significant
complication of the therapy. Multiple exposures to this
chemotherapeutic agent can cause sometimes life-threatening
events, requiring discontinuation of treatment. However, while
carboplatin-associated HSRs have been described extensively and
analyzed in large cohorts of adult patients, our knowledge of their
features in pediatric patients remains limited.
INCIDENCE
Allergic hypersensitivity to carboplatin is frequently reported
in children, and the extensive use of carboplatin-based
chemotherapy has brought with it an increase in allergic
reactions (Allen et al., 1987; Chang et al., 1995; Lazzareschi et al.,
2002). Carboplatin HSR has been described mostly in pediatric
series of LGG, where the reported incidence is up to 47%
depending on the schedules of administration (Lafay-Cousin
et al., 2008; Dodgshun et al., 2016).
In the initial reports on the carboplatin-vincristine
combination in pediatric LGG, Packer et al. (1997) observed
a frequency of 7%. In a cohort of 29 children with LGG,
Lazzareschi et al. (2002) reported six patients (20%) who
developed HSRs to carboplatin. In the retrospective, cooperative
Canadian study 42% of children with LGG who received a
carboplatin-based chemotherapy regimen developed HSRs
during the course of the treatment (Lafay-Cousin et al., 2008).
Genc et al. (2012) observed a frequency of 40% in their study.
Recently, carboplatin hypersensitivity was documented in
47% of patients by Dodgshun et al. (2016), and in the study
by Shah et al. (2016) of 144 children with LGG treated with
carboplatin and vincristine, 56 (39%) experienced an HSR to
carboplatin.
CLINICAL FEATURES
Carboplatin can induce mild to moderate and severe HSRs which
may develop acutely during infusion or within minutes, hours, or
days after the drug has been delivered.
Clinical evidence of HSRs are graded 0 through 5 (grade 5
being death) by using the NCI Common Terminology Criteria
for Adverse Events [CTCAE] (2010, CTCAE v. 4.03).
Mild and moderate reactions include all cutaneous reactions
(flushing, pruritus, urticaria, angioedema, and maculopapular
rash) not associated with symptoms affecting other organ
systems. Severe reactions include chest pain, dyspnea, oxygen
desaturation, edema/angioedema, changes in blood pressure and
cardiovascular collapse.
Urticaria and facial rash may be the first and most common
manifestations of hypersensitivity (Lazzareschi et al., 2002) and
Markman et al. (1999) reported more than 50% of patients
developing at least moderately severe symptoms. Symptoms
usually resolved quickly with antihistamines and steroids.
More severe reactions and systemic anaphylaxis may be
life-threatening (Cefalo et al., 2010). It is possible that carboplatin
HSRs are not always recognized. Often, the early signs
are subtle and may include only a mild rash and a mild
bronchospasm (Wiesner et al., 2004). Patients should be alerted
and appropriately instructed so that symptoms are promptly
recognized and the diagnosis of HSR established to prevent
potentially dangerous retreatment.
PATHOPHYSIOLOGY
The exact mechanism of carboplatin HSRs remains unclear, but
the different clinical patterns of allergic reactions suggest that
various immunological and non-immunological mechanisms
are involved (Zanotti et al., 2001). Likelihood of type I IgE-
mediated hypersensitivity increases with the rising incidence
of hypersensitivity with repeated doses and with positive skin
prick test reactions to platinum compounds (Leguy-Seguin
et al., 2007). Carboplatin can act as a hapten and cause a
type I IgE-mediated, histaminergic reaction with release of
inflammatory molecules (Navo et al., 2006; Makrilia et al., 2010).
Type I IgE-mediated hypersensitivity may be linked to early
onset manifestations, such as itching, chest pain, rash, and
anaphylactic reactions. An alternative to the type I IgE-mediated
mechanism is type IV hypersensitivity, mediated by T cells, a
delayed inflammatory reaction occurring hours or days after the
infusion.
Some authors have tried to predict HSRs by using skin
testing (Zanotti et al., 2001; Cefalo et al., 2010). Zanotti et al.
(2001) developed a skin-test protocol for adult patients with
gynecological malignancies and first demonstrated that skin
testing for carboplatin made it possible to identify patients at risk
for HSRs with a 99% negative predictive value. A cohort of 47
patients received a 0.02 ml intradermal injection of an undiluted
aliquot of carboplatin 1 h before each course of chemotherapy.
A negative skin test accurately predicted the absence of HSRs in
166 out of 168 courses of chemotherapy. Markman et al. (2003)
performed skin tests on 126 women with gynecological cancer
30 min before each carboplatin treatment after the sixth cycle.
They reported that skin tests had been positive in six out of seven
patients who later developed anaphylaxis during carboplatin
re-administration, finding a 98.5% negative predictive value.
Therefore, a negative carboplatin skin test seems to predict with
reasonable reliability the absence of a severe HSR with subsequent
infusion of the drug. However, the implications of a positive test
remain less certain and the limited experience with continued
treatment suggests that this approach must be undertaken with
considerable caution. According to Lazzareschi et al. (2002), the
lack of sensitivity in skin tests could be explained by the fact that
the molecular weight of carboplatin (373.272 g/mol) is low and it
is not immunogenic in the native form.
RISK FACTORS
A greater risk of developing an HSR has been observed in
younger patients than in older age groups of children (Genc
et al., 2012); risk is also greater in girls (Lafay-Cousin et al.,
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2008) and in patients with a prior history of allergy to other
drugs (Ruggiero et al., 2010). No significant correlation was
found between the occurrence of carboplatin HSRs and previous
surgery, radiotherapy or tumor location (Genc et al., 2012).
The risk of hypersensitivity is related to the cumulative
number of infusions rather than to the cumulative dose of
carboplatin (Chang et al., 1995), thus it increases with repeated
exposure to carboplatin (Schiavetti et al., 1999; Yu et al., 2001;
Lazzareschi et al., 2002; Wiesner et al., 2004). The first HSR
generally occurs between the 7th and the 10th carboplatin
infusion (Schiavetti et al., 1999; Lazzareschi et al., 2002; Wiesner
et al., 2004). Indeed HSRs are uncommon during the first few
cycles and the incidence of reactions occurs mainly between the
7th and the 15th carboplatin infusion and may develop acutely
during infusion or within minutes, hours, or days after the drug
has been delivered (Genc et al., 2012).
Weekly dosing schedules of carboplatin have been identified
as a risk factor for HSR in brain tumor patients (Yu et al., 2001).
However, in the Canadian study (Lafay-Cousin et al., 2008),
patients who received a weekly schedule had an incidence of
HSR comparable to that of patients who were treated by monthly
dosing, although HSR occurred 3 months earlier in the weekly
dosing group.
According to Markman et al. (1999), the threshold for the
manifestation of a reaction is expected to drop with each
treatment because the patient is sensitized during the first
treatment, and retreatment with the same drug provides the
additional immunological stimulation necessary for a reaction.
Moreover, an increased severity of HSRs might be linked
to re-exposure. Genc et al. (2012) reported seven out of eight
patients had worsening hypersensitivity symptoms. Wiesner et al.
(2004) observed grade III or IV reactions after re-exposure in
five out of nine LGG patients with initial grade II reactions.
The Canadian study found that the frequency of grade III and
IV reactions rose from 18.2% at the first HSR episode to 41.7%
for the second episode (Lafay-Cousin et al., 2008). Dodgshun
et al. (2016) reported grade III reactions on rechallenge in two
patients who initially experienced grade I and II reactions. In the
study by Shah et al. (2016), 19 patients experienced a subsequent
high-grade HSR (Grade III or IV) after initiating carboplatin
rechallenge. In any case, Chang et al. (1995) did not document
any increase in severity of HSR after re-exposure. The main
issue is related to the possibility that an increased severity of
hypersensitivity after re-exposure might expose the patient to the
risk of anaphylaxis (Kook et al., 1998; Yu et al., 2001).
MANAGEMENT
Chemotherapy protocols based on a combination of carboplatin
and other drugs produced good results in terms of progression-
free survival rate, as in LGG. Thus, when a patient shows a
response to a carboplatin-based regimen, strategies that alter
the HSRs may be justified as an attempt to salvage an effective
therapy.
However, when HSRs occur early in treatment, it may be
harder to predict the response to treatment and the benefit of
continuing carboplatin may be inferior to the risk of a more
severe allergic reaction. Therefore, according to International
Society of Pediatric Oncology LGG protocol, in patients
developing an allergy to carboplatin during consolidation,
therapy shall be continued with alternative drug combinations
(cisplatin/vincristine and cyclophosphamide/vincristine) (Azizi,
2010). The substitution of carboplatin with another platinum
compound (such as cisplatin) may be limited by cross-reactivity
of platinum-specific IgE (Pagani, 2010). The cisplatin and
cyclophosphamide combination showed efficacy when alternated
with carboplatin in the French “BABY-SFOP” LGG study
(Rakotonjanahary et al., 2015). Despite its effectiveness, however,
cisplatin is more ototoxic and nephrotoxic than carboplatin
(Bertolini et al., 2004). In patients receiving carboplatin, the
incidence of ototoxicity is approximately 7% (Dean et al., 2008;
Jehanne et al., 2009). In patients receiving cumulative cisplatin
doses of ≤200 mg/m2, 200–400 mg/m2, and ≥400 mg/m2, the
incidence increases to 59, 68, and 65%, respectively (Peleva
et al., 2014). Moreover, severe nephrotoxicity has not been
reported during carboplatin-therapy and reduction of glomerular
filtration rate to less than 50% is less frequent than with
cisplatin. Moreover, cisplatin combined with cyclophosphamide
could further damage renal function, therefore, in order to
limit cumulative doses of these agents, no more than five
cycles of both combinations shall be given. Therefore, to
date the vincristine/carboplatin combination remains the most
widely adopted multi-agent chemotherapy for childhood LGG.
Of course, in patients sensitive to carboplatin the benefit of
continuing this agent must be traded off against the risk of more
severe reactions in view of the fact that no precise way to identify
patients likely to react or to predict the severity of the reactions
has yet been found.
To date, various desensitization and/or premedication
protocols have been proposed, in children developing carboplatin
HSR as a late event.
Pretreatment with steroids or antihistamines usually fails
to prevent IgE-mediated reactions. The effectiveness of oral
antihistamines has been found only in mild or moderate cases of
carboplatin HSRs (Genc et al., 2012); moreover, the prolonged
use of steroids is associated with long-term side effects in
children and adolescents, such as mood changes, weight gain, and
osteoporosis (Lafay-Cousin et al., 2008). The literature points to a
low efficacy of premedication alone in re-exposure to carboplatin
in patients with HSR. Aquino et al. (1999) and Heath et al.
(2003) have reported complete failure of premedication (100%
discontinuation rate). In Chang et al. (1995) and Wiesner et al.
(2004) the effectiveness of premedication was 20 and 28.6%,
respectively.
To date, several desensitization protocols for re-administering
carboplatin have been implemented and have produced
promising results (Markman et al., 1999; Lazzareschi et al.,
2002; Lee et al., 2009; Castells et al., 2012) (Table 1). Drug
desensitization is a procedure designed to obtain temporary
clinical tolerance, especially in cases where the patient seems to
have benefited from the drug (Castells, 2006; Lee et al., 2009;
Castells et al., 2012). The complete target dose of the drug is
administered in separate incremental steps in order to obtain an
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TABLE 1 | Success rate of desensitization in patients with hypersensitivity reactions to carboplatin.










Lazzareschi et al., 2002 29 6 (20.6%) 6 (100%) 6 6/6 (100%)
Lafay-Cousin et al., 2008 105 44 (41.9%) 34 (77.2%) 12 1/12 (8.3%)
Genc et al., 2012 50 20 (40%) 19 (95%) 9 6/9 (66.6%)
Dodgshun et al., 2016 59 16 (27.1%) 10 (62.5%) 10 2/10 (20%)
Shah et al., 2016 144 56 (38.9%) 55 (98.2%) 25 19/25(76%)
inhibition of mast-cell activation for the specific drug antigen.
Sometimes this procedure is accompanied by a more intense
premedication to prevent any risk of reaction (Genc et al.,
2012). It is possible that the administration of small, increasing
doses of antigen delivered at fixed time intervals may consume
IgE antibodies slowly without acute reactions by inducing
a prolonged hypo-responsiveness to triggering doses of the
desensitizing antigen. Successful re-exposure to carboplatin is
defined as the ability to complete the full planned course of
treatment. All other cases where carboplatin is discontinued are
considered a failure of re-exposure.
In Lazzareschi et al. (2002) described a successfully modified
desensitization protocol for carboplatin administration in six
children who had an allergic reaction to the drug. The protocol
consisted of a standard dose of carboplatin (175 mg/m2 in
100 ml saline solution) at an increasing infusion rate, without
premedication. The drug was administered every 30 min starting
with a dose of 0.3 mg/m2/min and reaching 2.4 mg/m2/min
in five steps (Lazzareschi et al., 2002) (Table 2). The protocol
allowed the patients to receive carboplatin without adverse
reactions in all re-treated patients. Genc et al. (2012) (Table 2)
implemented a seven-step desensitization protocol in nine
children affected by LGG, with a success rate of 66.6%. Patients
were premedicated with pheniramine maleate (1 mg/kg/dose
IV) and dexamethasone (0.3 mg/kg/dose IV) and the drugs
were infused progressively every 15 min, beginning with a
0.1 mg/dose bolus, up to a 25 mg/dose. In the study by Shah
et al. (2016) patients were re-exposed to therapy with carboplatin
using precautionary measures, which included: prolongation
of infusion (1–2 h); premedication with H1 antagonists; H2
antagonists, and corticosteroids. In patients with recurrent
reactions despite precautionary measures, and in patients in
which the first reaction was considered severe, a desensitization
scheme was proposed which involved the administration of
carboplatin in gradually increasing doses, from as low as
0.01 mg/min up to a maximum of 1.5 mg/min in nine progressive
increments (Table 2). The success rate was 76%.
However, according to Lafay-Cousin et al. (2008)
and Dodgshun et al. (2016), the desensitization protocol
demonstrated low efficacy, due to differences in starting dose,
infusion rate and number of increments compared with other
studies. In the Canadian study, the desensitization protocol
consisted of a progressive increase in the rate of carboplatin
infusion over various periods (from 1 h to 6 h) according
to previously described schedules (doses of 1, 2.5, 5, 10, 25,
and 50 mg of carboplatin infused at 1 mg/min every 15 min;
the remainder of the dose was infused at the standard rate of
200 mg/h) (Broome et al., 1996; Ogle et al., 2002). Nevertheless,
among the 12 patients who underwent desensitization and
premedication (antihistamine with or without corticosteroid
initiated from 3 days to 1 h before carboplatin infusion), only
one patient (8.3%) was able to complete his carboplatin therapy
(Lafay-Cousin et al., 2008). In this study the lower success rate
of desensitization may be due to the starting dose being higher
than in other studies (Lazzareschi et al., 2002; Genc et al., 2012;
Shah et al., 2016). Dodgshun et al. (2016) reported a success rate
of 20%. All patients received premedication with dexamethasone
(between 0.05 and 0.15 mg/kg delivered via IV 1 h prior to
carboplatin) and cetirazine (∼0.2 mg/kg delivered orally 1 h
prior to carboplatin) and all but one, were exposed to the
TABLE 2 | Effective desensitization protocols.
Lazzareschi et al., 2002 Genc et al., 2012 Shah et al., 2016
Step Infusion rate
(mg/m2/min)
Time (min) Step Infusion rate (mg/m2/min) Time (min) Step Infusion rate (mg/m2/min) Time (min)
1 0.3 30 1 0.1 15 1 0.01 15
2 0.6 30 2 1 15 2 0.1 15
3 1.2 30 3 2.5 15 3 0.5 15
4 1.8 30 4 5 15 4 1 15
5 2.4 30 5 10 15 5 1 15
6 25 15 6 1 15
7 Remaining 15 7 1 15
dose 8 1.5 15
9 1.5 15
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desensitization diagram with subsequent infusions of increasing
doses of carboplatin according to the scheme described by
Confino-Cohen et al. (2005). The protocol consisted of an initial
infusion of 1/1000 of the total dose in the first 90 min, followed
by 1/100 of the total dose for an additional 90 min, up to 1/10
in 90 min and the remainder of the dose in the last 90 min.
Desensitization was not effective in this cohort. It is not clear
why the success rate is so different from what was previously
reported in adult literature. This may be due to the lack of a
gradual increase in the rate of infusion (from 0.6 mg/m2/min to
5.5 mg/m2/min in the fourth step), and to the limited number of
increments.
CONCLUSION
As carboplatin has been used with increasing frequency for the
management of childhood cancers, HSRs have emerged as a
significant complication of the therapy although their features
involving pediatric patients remain limited. HSRs occur mainly
between the 7th and the 15th carboplatin infusion, therefore
attention must be paid to the cumulative number of infusions
rather than to the cumulative dose.
When a patient shows a response to a carboplatin-based
regimen, strategies that alter the HSRs may be justified as an
attempt to salvage an effective therapy, although the benefits
of continuing the carboplatin chemotherapy should always
be carefully weighed against the risks of potential dangerous
complications.
Patients with an early onset allergic reaction should switch to
alternative chemotherapy regimens that offer a good efficacy rate
in order to avoid any risk associated with re-exposure. Thus, the
likelihood of completing therapy is higher if restricted to patients
with a late onset reaction.
Premedication with anti-histamines and/or corticosteroids is
able to prevent an allergic reaction only in a limited number of
patients with mild or moderate reactions. Several desensitization
protocols have been implemented in order to re-administer
carboplatin with various efficacy results. Hypothesis on their
effectiveness to be further investigated are based on the potential
role of the starting dose, infusion rate and number of increments.
A lower starting dose, a slow infusion, and a number of
increments greater than or equal to 4 are associated with a greater
probability of success.
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